EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
|Videos|April 25, 2022
Dr. Samantha Pulliam describes the leva Pelvic Health System
Author(s)Urology Times staff
“This is a unique device in that it shows motion-based biofeedback,” says Samantha Pulliam, MD.
Advertisement
In this video, Samantha Pulliam, MD, discusses the leva Pelvic Health System and how it works. Pulliam is chief medical officer for Renovia Inc.
Advertisement
Related to this article
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
A recap of the FDA submissions and regulatory decisions in urology from August 2026.
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5